ROL' FARMAKOGENETIKI V INDIVIDUALIZATsII PROTIVOOPUKhOLEVOY KhIMIOTERAPII


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Individual approach to the selection of anticancer chemotherapy can be based not only on the biological parameters of the tumor, but also on the genetically-determined characteristics of metabolism of cytotoxic drugs that affect their efficacy and toxicity. These features are exploring by pharmacogenetics; they are associated with polymorphisms (DNA variations) of genes involved in transport, metabolism and cytotoxic effect of the drugs. Pharmacogenetic testing is used for the individualizing of chemotherapy with irinotecan, fluorouracil, and mercaptopurine in some clinics; inclusion of tamoxifen in this list has been widely discussed. With respect to the role of other drugs, the role of pharmacogenetic testing is under investigation.

Full Text

Restricted Access

About the authors

A. A Moiseev

References

  1. Relling M.V., Giacomini K.M. Pharmacogenetics. In: Goodman & Gilman's The Pharmacologic Basis of Therapeutics, 12th ed. McGraw-Hill, 2011:145-68.
  2. Weng L., Zhang L., Peng Y., Huang R.S. Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics 2013;14:315-24.
  3. Wang L., McLeod H.L., Weinshilboum R.M. Genomics and drug response. N Engl J Med 2011;364:1144-53.
  4. Marsh S., Hoskins J.M. Irinotecan pharmacogenomics. Pharmacogenomics 2010;11: 1003-10.
  5. Fujiwara Y., Minami H. An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics 2010;11:391-406.
  6. Ezzeldin H.H., Diasio R.B. Predicting fluorouracil toxicity: can we finally do it? J Clin Oncol 2008;26:2080-82.
  7. Amstutz U., Froehlich T.K., Largiadr C.R. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 2011;12:1321-36.
  8. Gervasini G., Vagace J.M. Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia. Front Genet 2012;3:249.
  9. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein and breast cancer resistance protein. Drug Metab Pharmacokinet 2012;27:85-105.
  10. Jabir R.S., Naidu R., Annuar M.A., et al. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics 2012;13:1979-88.
  11. Niemi M., Pasanen M.K., Neuvonen P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63:157-81.
  12. Nakanishi T., Tamai I. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab Pharmacokinet 2012;27:106-21.
  13. Burger H., Loos W.J., Eechoute K., Verweij J., Mathijssen R.H., Wiemer E.A. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 2011;14:22-34.
  14. Ciarimboli G., Lancaster C.S., Schlatter E., et al. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 2012;18:1101-108.
  15. Yonezawa A., Inui K. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 2011;81:563-68.
  16. Del Re M., Michelucci A., Simi P., Danesi R. Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer Treat Rev 2012; 38:442-50.
  17. Turpeinen M., Zanger U.M. Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metabol Drug Interact 2012;27:185-97.
  18. Brauch H., Schroth W., Goetz M.P., et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2013;31: 176-80.
  19. Schroth W., Goetz M.P., Hamann U., et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429-36.
  20. Ishimoto T.M., Ali-Osman F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in E. coli. Pharmacogenetics 2002:12:543-53.
  21. Köberle B., Tomicic M.T., Usanova S., Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 2010;1806:172-82.
  22. Khrunin A.V., Moisseev A., Gorbunova V., Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010;10:54-61.
  23. Marsh S., Paul J., King C.R., et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007;25:4528-35.
  24. McLeod H.L., et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010;28: 3227-33.
  25. Todd R.C., Lippard S.J. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009;1:280-91.
  26. Bohanes P., Labonte M.J., Lenz H.J. A review of excision repair cross-complementation group 1 in colorectal cancer. Clin Colorectal Cancer 2011;10:157-64.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies